Skip Navigation

JNCI Journal of the National Cancer Institute 2007 99(6):421-422; doi:10.1093/jnci/djk141
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Ross, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ross, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2007.

NEWS

For Organ Transplant Recipients, Cancer Threatens Long-term Survival

Karen Ross

The first 10% of the full text of this article appears below.

Transplant recipients are three to four times more likely to develop cancer than the general population, and those that do get cancer face a much greater chance of dying from their disease.

Among kidney and heart recipients who have survived at least 3 years after a transplant, cancer is poised to become the leading cause of death over the next 20 years, said Joseph Buell, M.D., of the University of Louisville Jewish Hospital.

However, promising early studies indicate that a relatively new immunosuppressant medication called sirolimus may help keep cancer among transplant recipients in check.

"I truly believe [sirolimus] will have an effect on cancer," said Edward Geissler, Ph.D., of the University of Regensburg Medical Center . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?